Altassian Joins with Williams Racing Team
Williams Racing and Atlassian are thrilled to announce a long-term title partnership that will usher in a new era for the iconic Formula 1 team as Atlassian Williams Racing.Williams, the joint-second most successful team in F1 history with 114 wins, nine Constructors’ Championships and seven Drivers’ Championships is joining forces with Atlassian (NASDAQ: TEAM), a leading provider of team collaboration and productivity software whose world-class platform serves over 300,000 customers across the globe.This partnership unites two organisations driven by teamwork: Atlassian’s AI-powered collaboration software empowers teams of 10 to 10,000+ people so they can plan and track work, align on goals and unleash knowledge seamlessly. For almost 50 years Williams has been competing in F1 which is the ultimate test of teamwork across a range of disciplines in pursuit of sporting success.Under the partnership, Atlassian becomes the Official Title Partner, Official Technology Partner and Official Collaboration Software partner. The multi-year commitment is the biggest partnership deal in Williams’ 48-year history, recognising its position as an icon of one of the most-popular and fastest-growing sports on the planet. It is another vote of confidence in the team’s comeback plan to transform and deliver future World Championship success.TEAM shares began Tuesday down $3.50, or 1.1%, to $319.44.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


